1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/07/2024 | NUVB | Buy Now | Nuvation Bio | $2.30 | 117.39% | HC Wainwright & Co. | Robert Burns | $4.5 → $5 | Maintains | Buy | Get Alert |
03/01/2024 | NUVB | Buy Now | Nuvation Bio | $2.30 | 117.39% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
11/22/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 95.65% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | Buy → Buy | Get Alert |
08/21/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 95.65% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | Buy → Buy | Get Alert |
05/05/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 117.39% | RBC Capital | Gregory Renza | $6 → $5 | Maintains | Outperform | Get Alert |
03/24/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 95.65% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | → Buy | Get Alert |
03/16/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 117.39% | Wedbush | David Nierengarten | → $5 | Reiterates | → Outperform | Get Alert |
03/16/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | 160.87% | RBC Capital | Gregory Renza | → $6 | Reiterates | → Outperform | Get Alert |
01/06/2023 | NUVB | Buy Now | Nuvation Bio | $2.30 | -13.04% | Jefferies | Michael Yee | $5 → $2 | Downgrade | Buy → Hold | Get Alert |
08/22/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | 95.65% | HC Wainwright & Co. | Robert Burns | $14 → $4.5 | Maintains | Buy | Get Alert |
08/02/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | 8.7% | BMO Capital | Evan Seigerman | $8 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
08/02/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | — | BTIG | Kaveri Pohlman | — | Downgrade | Buy → Neutral | Get Alert |
05/11/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | 508.7% | RBC Capital | Gregory Renza | $15 → $14 | Maintains | Outperform | Get Alert |
05/04/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | 508.7% | HC Wainwright & Co. | Robert Burns | → $14 | Initiates | → Buy | Get Alert |
03/22/2022 | NUVB | Buy Now | Nuvation Bio | $2.30 | 421.74% | BMO Capital | Evan Seigerman | $17 → $12 | Maintains | Outperform | Get Alert |
04/06/2021 | NUVB | Buy Now | Nuvation Bio | $2.30 | 552.17% | RBC Capital | Mark Dwelle | — | Initiates | → Outperform | Get Alert |
The latest price target for Nuvation Bio (NYSE: NUVB) was reported by HC Wainwright & Co. on March 7, 2024. The analyst firm set a price target for $5.00 expecting NUVB to rise to within 12 months (a possible 117.39% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Nuvation Bio (NYSE: NUVB) was provided by HC Wainwright & Co., and Nuvation Bio maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvation Bio was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
While ratings are subjective and will change, the latest Nuvation Bio (NUVB) rating was a maintained with a price target of $4.50 to $5.00. The current price Nuvation Bio (NUVB) is trading at is $2.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.